Fate Therapeutics Announces First Patient Treated In Phase 1b Clinical Trial Of FT1050 For Hematopoietic Stem Cell …
Fate Therapeutics, Inc. announced today that the first patient has been treated in a Phase 1b clinical trial of FT1050, a small molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem cell (HSC) number and function through its activation of key pathways that guide cell fate.
[Read the full article here]Related News:
Fate Therapeutics Announces First Patient Treated In Phase 1b Clinical Trial Of FT1050 For Hematopoietic Stem Cell Support
First Patient Treated In Osiris Phase II Stem Cell Trial For Heart Attacks
Stem Cell Therapeutics Corp. Announces The FDA Has Lifted Its Clinical Hold On The Phase IIb Stroke Trial